US 11,807,687 B2
Therapeutic compositions comprising anti-NRP2 antibodies
Luke Burman, San Diego, CA (US); Yeeting Chong, San Diego, CA (US); Leslie Ann Greene, San Diego, CA (US); David King, Encinitas, CA (US); Zhiwen Xu, San Diego, CA (US); and Ryan Andrew Adams, San Diego, CA (US)
Assigned to aTyr Pharma, Inc., San Diego, CA (US)
Filed by aTyr Pharma, Inc., San Diego, CA (US)
Filed on Oct. 2, 2020, as Appl. No. 17/062,100.
Claims priority of provisional application 63/024,960, filed on May 14, 2020.
Claims priority of provisional application 62/910,042, filed on Oct. 3, 2019.
Prior Publication US 2021/0163606 A1, Jun. 3, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); A61K 39/001103 (2018.08); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A therapeutic composition, comprising a physiologically-acceptable carrier and at least one antibody or antigen-binding fragment thereof that specifically binds to a human neuropilin-2 (NRP2) polypeptide (anti-NRP2 antibody), wherein the at least one antibody or antigen-binding fragment thereof comprises:
a heavy chain variable region (VH) sequence that comprises complementary determining region VHCDR1, VHCDR2, and VHCDR3 sequences; and
a light chain variable region (VL) sequence that comprises complementary determining region VLCDR1, VLCDR2, and VLCDR3 sequences, wherein:
the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 19-21, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 22-24, respectively.